Corcept.

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has …WebCorcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998. Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical …Clinical Trials. View Corcept Therapeutics clinical trials, research and pipeline information for compounds such as CORT118335, CORT125281, and more.Corcept Therapeutics Q1 2021 Earnings Conference Call. Feb 8, 2021 at 5:00 PM EST.Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, ...

3 hari yang lalu ... Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View. Corcept's (CORT) third-quarter 2023 earnings and revenues surpass estimates. The ...Mar 28, 2023 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ... Korlym (mifepristone) Tablets, 300 mgCompany: Corcept TherapeuticsApplication No.: 202107Approval Date: 02/17/2012. Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. Approval Letter (s) (PDF) Summary Review (PDF) Officer/Employee List (PDF) Cross …Web

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements.

MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …WebCorcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022. Second quarter operating expenses were $88.1 million, compared to $72.0 million in the second quarter of 2022, due to increased spending on our development programs and to support the expansion of our clinical development …WebData from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021; Results show statistically significant and clinically relevant benefit experienced by women with recurrent platinum-resistant ovarian cancer who were treated with nab-paclitaxel plus Corcept’s proprietary …On November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...WebMar 30, 2022 · About Corcept’s Ovarian Cancer Program. The data in this release come from Corcept’s 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. 5 The women who entered the trial had experienced disease progression on prior lines of therapy. The median ...

Jul 26, 2023 · November 1, 2023. Corcept Appoints Monica Tellado as President, Emerging Markets. October 26, 2023. Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) October 25, 2023. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call. August 2, 2023.

Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side. The tablets are not scored. 4 CONTRAINDICATIONS KORLYM is contraindicated in: • Pregnancy [See Dosage and Administration (2.1), Use in Specific Populations (8.1,8.3)]

Dec 31, 2021 · MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021. Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) – Zacks Research increased their Q1 2024 earnings per share estimates for Corcept Therapeutics in a research report issued on Wednesday, November 29th.Zacks Research analyst K. Das now expects that the biotechnology company will post earnings per share of $0.18 for the …About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with …WebDescription. Corcept Therapeutics Inc. is a pharmaceutical company that discovers and develops drugs for the treatment of severe meta... more. Solutions.Corcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as …MENLO PARK, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has initiated DAZALS – a Phase 2 trial of its proprietary ...Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.

Jun 24, 2022 · Corcept's work represents a unique opportunity for a small biopharmaceutical company. The 240-person business has largely flown under the radar since 2012, when it won its first and only Food and ... Dec 5, 2023 · Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ... Joseph K. Belanoff, MD. Joseph K. Belanoff, M.D. is a co-founder of our company and has served as a member of our Board and our Chief Executive Officer since Corcept’s inception in 1999, and as our President since 2014. Dr. Belanoff is an Adjunct Professor of Psychiatry at Stanford University (School of Medicine), where he has held positions ...MD with 20+ years of experience in the biopharma industry leading multi-functional teams to drive key Clinical Development strategies.Mar 6, 2023 · Corcept may not consummate the tender offer described in this press release and, if the tender offer is consummated, cannot provide any assurances regarding the final terms of the tender offer. For more information, go to www.korlym.com or www.corcept.com or call 1-855-456-7596. This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 11/2019 2. Created Date:Alternative Names: ADS-108297; CORT-108297. Latest Information Update: 29 Nov 2022. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in ...Web

Jul 28, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...

The Corcept name, the Corcept logo, and all related names, logos, product, and service names, designs and slogans, whether appearing in large print or with the trademark symbol, are the trademarks or trade dress of Corcept in the US and other countries. 6.3 Ownership of Feedback.Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and …WebA class action complaint has been filed against Corcept, which alleges that defendants made materially false and/or misleading statements, and failed to ...Corcept Therapeutics overview Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol …Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...Dec 7, 2021 · Menlo Park, California-based Corcept last year made over $353 million from sales of Korlym, the company's only drug, according to a filing with the U.S. Securities and Exchange Commission.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...Web

We are raising our 2023 revenue guidance again to a range of $470 million to $480 million, up from $455 million to $470 million. Net income was $31.4 million or $0.28 per share in the third ...Corcept Therapeutics (NASDAQ: CORT ) Incorporated (Nasdaq: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has commenced …WebMENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has …WebMar 31, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ... Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side. The tablets are not scored. 4 CONTRAINDICATIONS KORLYM is contraindicated in: • Pregnancy [See Dosage and Administration (2.1), Use in Specific Populations (8.1,8.3)] Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us!Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis ...WebThe Clinical Trial Manager (CTM) will independently manage all clinical aspects of a medium to large clinical study or up to two smaller clinical studies. This role will work closely with cross functional teams, vendors, sites and CRO (when applicable) to ensure compliance with protocol and the overall clinical objective. Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.06. The biotechnology company earned $123.60 million during the quarter, compared to analyst estimates of $119. ... Corcept Therapeutics overview Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym …

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.Web23 Mei 2023 ... Affiliations · Corcept Therapeutics, 149 Commonwealth Dr, Menlo Park, CA 94025, USA. Electronic address: [email protected]. · Corcept ...Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking Statements.Instagram:https://instagram. warren buffett letter to shareholdersstock trading ai softwarehong.kong stock markettop rated banks in tennessee Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders ...Web aetna savings dental planwhere can you sell a broken iphone Corcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million, compared to $69.8 million ...Web kscp stock price today Jul 26, 2023 · November 1, 2023. Corcept Appoints Monica Tellado as President, Emerging Markets. October 26, 2023. Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) October 25, 2023. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call. August 2, 2023. The Clinical Trial Manager (CTM) will independently manage all clinical aspects of a medium to large clinical study or up to two smaller clinical studies. This role will work closely with cross functional teams, vendors, sites and CRO (when applicable) to ensure compliance with protocol and the overall clinical objective. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...